1. Home
  2. GANX vs HYPR Comparison

GANX vs HYPR Comparison

Compare GANX & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • HYPR
  • Stock Information
  • Founded
  • GANX 2017
  • HYPR 2014
  • Country
  • GANX United States
  • HYPR United States
  • Employees
  • GANX N/A
  • HYPR N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • HYPR Medical Specialities
  • Sector
  • GANX Health Care
  • HYPR Health Care
  • Exchange
  • GANX Nasdaq
  • HYPR Nasdaq
  • Market Cap
  • GANX 69.0M
  • HYPR 55.9M
  • IPO Year
  • GANX 2021
  • HYPR N/A
  • Fundamental
  • Price
  • GANX $1.64
  • HYPR $1.39
  • Analyst Decision
  • GANX Strong Buy
  • HYPR Strong Buy
  • Analyst Count
  • GANX 5
  • HYPR 3
  • Target Price
  • GANX $8.20
  • HYPR $1.28
  • AVG Volume (30 Days)
  • GANX 614.4K
  • HYPR 249.0K
  • Earning Date
  • GANX 11-13-2025
  • HYPR 11-11-2025
  • Dividend Yield
  • GANX N/A
  • HYPR N/A
  • EPS Growth
  • GANX N/A
  • HYPR N/A
  • EPS
  • GANX N/A
  • HYPR N/A
  • Revenue
  • GANX N/A
  • HYPR $10,797,000.00
  • Revenue This Year
  • GANX N/A
  • HYPR $12.92
  • Revenue Next Year
  • GANX N/A
  • HYPR $32.10
  • P/E Ratio
  • GANX N/A
  • HYPR N/A
  • Revenue Growth
  • GANX N/A
  • HYPR N/A
  • 52 Week Low
  • GANX $1.36
  • HYPR $0.53
  • 52 Week High
  • GANX $3.19
  • HYPR $1.90
  • Technical
  • Relative Strength Index (RSI)
  • GANX 43.33
  • HYPR 63.44
  • Support Level
  • GANX $1.55
  • HYPR $1.06
  • Resistance Level
  • GANX $1.78
  • HYPR $1.47
  • Average True Range (ATR)
  • GANX 0.13
  • HYPR 0.08
  • MACD
  • GANX -0.03
  • HYPR 0.01
  • Stochastic Oscillator
  • GANX 18.00
  • HYPR 80.49

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

Share on Social Networks: